ANIP
ANI Pharmaceuticals, Inc.NASDAQHealthcare$74.21-2.30%ClosedMarket Cap: $1.67B
As of 2026-04-06
Valuation
P/E (TTM)
21.97
PEG
0.04
P/B
2.86
P/S
1.96
EV/EBITDA
7.86
DCF Value
$1,140.11
FCF Yield
7.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.1%
Operating Margin
12.6%
Net Margin
8.6%
ROE
15.5%
ROA
5.3%
ROIC
7.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $247.1M | 96.2% | $48.2M | $27.5M | $1.17 | — |
| FY 2025 | $883.4M | 51.0% | $81.2M | $78.3M | $3.32 | — |
| Q3 2025 | $227.8M | 49.1% | $22.8M | $24.1M | $1.13 | — |
| Q2 2025 | $211.4M | 64.7% | $13.9M | $8.5M | $0.36 | — |
| Q1 2025 | $197.1M | 62.9% | $26.2M | $15.7M | $0.69 | — |
| Q4 2024 | $190.6M | 57.9% | $-4.4M | $-10.3M | $-0.55 | — |
| FY 2024 | $614.4M | 59.3% | $584.0K | $-18.5M | $-1.04 | — |
| Q3 2024 | $148.3M | 57.5% | $-20.5M | $-24.2M | $-1.27 | — |
| Q2 2024 | $138.0M | 58.2% | $5.2M | $-2.3M | $-0.14 | — |
| Q1 2024 | $137.4M | 64.2% | $20.3M | $18.2M | $0.83 | — |
| Q4 2023 | $131.7M | 59.4% | $6.7M | $1.2M | $0.04 | — |
| FY 2023 | $486.8M | 62.7% | $47.0M | $18.8M | $0.94 | — |